10.1016/j.ejmech.2011.08.021
The study presents the design, synthesis, and evaluation of a novel series of indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists. These compounds were developed to target cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, which are G protein-coupled receptors involved in various physiological processes and have therapeutic potential in conditions such as osteoporosis, multiple sclerosis, Alzheimer's disease, and cancer, among others. The researchers introduced a biphenyl moiety as a novel lipophilic indole 3-acyl substituent and replaced the 3-carbonyl tether with a carboxamide linker to improve physicochemical properties. They also designed azaindole (pyrrolopyridine) nuclei as indole bioisosteres to enhance lipophilicity and aqueous solubility. The purpose of these chemical modifications was to identify high-affinity CB1/CB2 dual cannabinoid receptor ligands with improved physicochemical properties, which could lead to more effective therapeutic agents. The study involved the synthesis and testing of various compounds, including indole-3-carboxamide derivatives and azaindoles, to evaluate their binding affinity, functional activity, and selectivity for CB1 and CB2 receptors.